Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118.
Department of Medicine, Boston University School of Medicine, Boston, MA 02118.
Proc Natl Acad Sci U S A. 2021 May 4;118(18). doi: 10.1073/pnas.2019282118.
Molecular events that drive the development of precancerous lesions in the bronchial epithelium, which are precursors of lung squamous cell carcinoma (LUSC), are poorly understood. We demonstrate that disruption of epithelial cellular polarity, via the conditional deletion of the apical determinant Crumbs3 (Crb3), initiates and sustains precancerous airway pathology. The loss of Crb3 in adult luminal airway epithelium promotes the uncontrolled activation of the transcriptional regulators YAP and TAZ, which stimulate intrinsic signals that promote epithelial cell plasticity and paracrine signals that induce basal-like cell growth. We show that aberrant polarity and YAP/TAZ-regulated gene expression associates with human bronchial precancer pathology and disease progression. Analyses of YAP/TAZ-regulated genes further identified the ERBB receptor ligand Neuregulin-1 (NRG1) as a key transcriptional target and therapeutic targeting of ERBB receptors as a means of preventing and treating precancerous cell growth. Our observations offer important molecular insight into the etiology of LUSC and provides directions for potential interception strategies of lung cancer.
分子事件驱动支气管上皮癌前病变的发展,这些病变是肺鳞状细胞癌(LUSC)的前身,但目前对此知之甚少。我们证明,通过条件性缺失顶端决定因子 Crumbs3(Crb3),破坏上皮细胞极性会引发并维持癌前气道病变。成年腔道上皮细胞中 Crb3 的缺失会促进转录调节因子 YAP 和 TAZ 的失控激活,这会刺激促进上皮细胞可塑性的内在信号和诱导基底样细胞生长的旁分泌信号。我们表明,异常的极性和 YAP/TAZ 调节的基因表达与人类支气管癌前病变和疾病进展相关。对 YAP/TAZ 调节基因的分析进一步确定了 ERBB 受体配体神经调节蛋白 1(NRG1)为关键转录靶点,靶向 ERBB 受体是预防和治疗癌前细胞生长的一种手段。我们的观察结果为 LUSC 的病因提供了重要的分子见解,并为潜在的肺癌干预策略提供了方向。